IEX Stock Analysis: IDEX | NYSE

Pumps, Valves, Medical Devices, Firefighting Equipment

Total Rating 76

Safety 90

Buy Signal 1.11

Specialty Industrial Machinery
Industry Rotation: +6.4

Market Cap: 16.9B
Avg Turnover: 140M

Risk 3d forecast

Volatility21.5%

VaR 5^th Pctl3.43%

VaR vs Median-3.39%

Reward TTM

Sharpe Ratio1.49

Rel. Str. IBD81

Rel. Str. Peer Group81.9

Character TTM

Beta0.990

Beta Downside0.977

Hurst Exponent0.541

Drawdowns 3y

Max DD34.60%

CAGR/Max DD0.16

CAGR/Mean DD0.37

EPS (Earnings per Share)

EPS CAGR: 0.01%
EPS Trend: 0.4%

Last SUE: 3.06
Qual. Beats: 6

Revenue

Rev. CAGR: 3.66%
Rev. Trend: 83.9%

Last SUE: 0.87
Qual. Beats: 4

Warnings

No concerns identified

Tailwinds

Idiosyncratic Leader

Confidence

Seasonality 11.7 years of data

Jan -0.6% 5

Feb +1.1% 5

Mar +0.5% 26

Apr -0.4% 19

May +0.3% 5

Jun -0.7% 8

Jul +4.2% 31

Aug -1.2% 19

Sep -1.6% 27

Oct -3.8% 12

Nov +6.3% 62

Dec -1.1% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IEX IDEX

IDEX Corporation (NYSE: IEX) is a U.S.-based industrial manufacturer that provides applied solutions through three reporting segments: Health & Science Technologies (HST), Fluid & Metering Technologies (FMT), and Fire & Safety/Diversified Products (FSDP). Its products are sold across the United States, North America, Europe, Asia, and other international markets.

The HST segment serves highly engineered, technology-intensive end markets, offering precision fluidics, pumps, processing and drying equipment, micro-precision components, pneumatic and sealing solutions, and items used in medical, pharmaceutical, and laboratory applications-including biocompatible devices and implantable products. Companies in this niche typically compete on engineering precision, customization, and intellectual property rather than volume.

The FMT segment focuses on fluid-handling equipment such as positive displacement pumps, valves, flow meters, provers, and injectors, along with related flow monitoring services. This is a core industrial process-control category serving industries like oil and gas, chemical processing, and water treatment.

The FSDP segment produces firefighting pumps, valves, controls, and rescue tools, as well as engineered band-and-clamp devices and precision dispensing/metering equipment for paints and colorants. The fire-safety side is tied to municipal and industrial safety equipment demand, while the dispensing side serves coatings and colorant formulation customers.

IDEX was incorporated in 1987 and is headquartered in Northbrook, Illinois, and operates as a diversified industrial conglomerate under the GICS Industrials sector, specifically within Industrial Machinery & Supplies & Components.

Headlines to Watch Out For

Health & Science segment drives organic revenue growth on biotech demand
Fluid & Metering margins pressured by oil and gas capex cycles
Bolt-on acquisition pipeline expands specialty industrial product portfolio

Piotroski VR-10 (Strict) 7.5

Net Income: 519.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.72 > 1.0
NWC/Revenue: 33.24% < 20% (prev 32.53%; Δ 0.71% < -1%)
CFO/TA 0.10 > 3% & CFO 716.7m > Net Income 519.5m
Net Debt (1.29b) to EBITDA (957.8m): 1.35 < 3
Current Ratio: 3.05 > 1.5 & < 3
Outstanding Shares: last quarter (74.2m) vs 12m ago -1.98% < -2%
Gross Margin: 44.70% > 18% (prev 43.40%; Δ 1.30% > 0.5%)
Asset Turnover: 51.94% > 50% (prev 48.59%; Δ 3.35% > 0%)
Interest Coverage Ratio: 11.68 > 6 (EBIT TTM 745.1m / Interest Expense TTM 63.8m)

Altman Z'' 5.48

A: 0.17 (Total Current Assets 1.77b - Total Current Liabilities 581.6m) / Total Assets 6.93b
B: 0.67 (Retained Earnings 4.66b / Total Assets 6.93b)
C: 0.11 (EBIT TTM 745.1m / Avg Total Assets 6.90b)
D: 1.37 (Book Value of Equity 4.01b / Total Liabilities 2.92b)
Altman-Z'' = 5.48 = AAA

Beneish M -2.96

DSRI: 1.07 (Receivables 547.8m/476.1m, Revenue 3.59b/3.34b)
GMI: 0.97 (GM 43.40% / 44.70%)
AQI: 0.97 (AQ_t 0.68 / AQ_t-1 0.70)
SGI: 1.07 (Revenue 3.59b / 3.34b)
TATA: -0.03 (NI 519.5m - CFO 716.7m) / TA 6.93b)
Beneish M = -2.96 (Cap -4..+1) = A

What is the price of IEX shares?

As of October 09, 2026, the stock is trading at USD 231.75 with a total of 828,192 shares traded. Over the past week, the price has changed by +1.15%, over one month by +3.03%, over three months by +6.46% and over the past year by +41.38%.

Current recommended Stop Loss: 223.80 (which is 3.4% or 1.7 ATR below the current price).

Is IEX a buy, sell or hold?

IDEX has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy IEX.

StrongBuy: 9
Buy: 1
Hold: 5
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IEX price?

Analysts Target Price	255.9	10.4%

IDEX (IEX) - Fundamental Data Overview as of 03 October 2026

Market Cap USD = 16.9b (16.9b USD * 1.0 USD.USD)
P/E Trailing = 33.0719
P/E Forward = 23.9808
P/S = 4.7261
P/B = 4.1512
P/EG = 1.715
Revenue TTM = 3.59b USD
EBIT TTM = 745.1m USD
EBITDA TTM = 957.8m USD
Long Term Debt = 1.86b USD (from longTermDebt, last quarter)
Short Term Debt = 27.0m USD (from shortTermDebt, last quarter)
Debt = 1.91b USD (from shortLongTermDebtTotal, last quarter) + Leases 26.6m
Net Debt = 1.29b USD (calculated: Debt 1.91b - CCE 621.3m)
Enterprise Value = 18.2b USD (16.9b + Debt 1.91b - CCE 621.3m)
Interest Coverage Ratio = 11.68 (Ebit TTM 745.1m / Interest Expense TTM 63.8m)
EV/FCF = 28.43x (Enterprise Value 18.2b / FCF TTM 641.5m)
FCF Yield = 3.52% (FCF TTM 641.5m / Enterprise Value 18.2b)
FCF Margin = 17.89% (FCF TTM 641.5m / Revenue TTM 3.59b)
Net Margin = 14.49% (Net Income TTM 519.5m / Revenue TTM 3.59b)
Gross Margin = 44.70% ((Revenue TTM 3.59b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Gross Margin QoQ = 46.36% (prev 44.89%)
Tobins Q-Ratio = 2.63 (Enterprise Value 18.2b / Total Assets 6.93b)
Interest Expense / Debt = 3.34% (Interest Expense 63.8m / Debt 1.91b)
Taxrate = 23.78% (162.0m / 681.3m)
NOPAT = 567.9m (EBIT 745.1m * (1 - 23.78%))
Current Ratio = 3.05 (Total Current Assets 1.77b / Total Current Liabilities 581.6m)
Debt / Equity = 0.48 (Debt 1.91b / totalStockholderEquity, last quarter 4.01b)
Debt / EBITDA = 1.35 (Net Debt 1.29b / EBITDA 957.8m)
Debt / FCF = 2.01 (Net Debt 1.29b / FCF TTM 641.5m)
Total Stockholder Equity = 4.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.53% (Net Income 519.5m / Total Assets 6.93b)
RoE = 12.91% (Net Income TTM 519.5m / Total Stockholder Equity 4.02b)
RoCE = 12.67% (EBIT 745.1m / Capital Employed (Equity 4.02b + L.T.Debt 1.86b))
RoIC = 9.17% (NOPAT 567.9m / Invested Capital 6.20b)
WACC = 8.76% (E(16.9b)/V(18.9b) * Re(9.46%) + D(1.91b)/V(18.9b) * Rd(3.34%) * (1-Tc(0.24)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.29 | Cagr: -1.00%
[DCF] Terminal Value 75.20% ; FCFF base≈619.7m ; Y1≈670.0m ; Y5≈823.0m
[DCF] Fair Price = 142.3 (EV 11.8b - Net Debt 1.29b = Equity 10.5b / Shares 73.7m; r=8.76% [WACC]; 5y FCF grow 9.28% → 2.50% )
EPS Correlation: 0.36 | EPS CAGR: 0.01% | SUE: 3.06 | # QB: 6
Revenue Correlation: 83.90 | Revenue CAGR: 3.66% | SUE: 0.87 | # QB: 4
EPS current Quarter (2026-09-30): EPS=2.24 | Chg30d=-0.05% | Revisions=+62% | Analysts=11
EPS current Year (2026-12-31): EPS=8.83 | Chg30d=+0.02% | Revisions=+81% | GrowthEPS=+11.0% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=9.63 | Chg30d=+1.20% | Revisions=+82% | GrowthEPS=+9.1% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +88% (up=36, down=1)